Our data demonstrate that co-treatment with ICB (αPD-L1) and tumor-specific CD4+ T-cell adoptive transfer can induce a tumor-specific CD4+ T lymphocyte proliferation response, which contributes to better tumor control. The gene discussed is CD4; the disease is neoplasm.